Biogen Inc. (BVMF:BIIB34)
| Market Cap | 214.42B +65.2% |
| Revenue (ttm) | 53.34B +2.3% |
| Net Income | 1.80B -78.4% |
| EPS | 2.27 -78.7% |
| Shares Out | n/a |
| PE Ratio | 100.27 |
| Forward PE | 16.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5 |
| Open | 227.24 |
| Previous Close | 229.00 |
| Day's Range | 227.24 - 230.10 |
| 52-Week Range | 137.90 - 230.10 |
| Beta | 0.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial numbers in USD Financial StatementsNews
Biogen, Eisai say LEADER findings show 76% lower rate of progression in AD
Eisai (ESAIY) and Biogen (BIIB) today announced new three-year real-world findings of 560 patients across 13 U.S. clinical sites from the largest analysis of the ongoing Lecanemab in Early Alzheimerās...
New Three-Year Real-World LEQEMBIĀ® Data Presented at CTAD 2026
Largest analysis of LEQEMBI LEADER study reported to date includes findings on amyloid clearance in routine clinical practice, delayed progression to moderate or severe AD, expanded subcutaneous maint...
Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
Biogen says diranersen demonstrates increasing clinical benefit at two years
Biogen (BIIB) announced new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide therapy targeting tau, in people living wi...
Biogen's Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer's Disease
CAMBRIDGE, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigation...
Biogen Transcript: Jefferies Global Healthcare Conference
Revenue growth is targeted for 2027, supported by commercial execution and portfolio products including Leqembi, Zurzuvae, Empaveli and Syfovre. December SLE results and upcoming pipeline readouts are key catalysts.
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
Benefits of continuous lecanemab treatment in early Alzheimer's disease accrue over time Lecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI 62% of patients...
TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease
CAMBRIDGE, England--(BUSINESS WIRE)--TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerati...
LEQEMBIĀ® Pen (Subcutaneous Formulation of LEQEMBIĀ®) Now Available in Japan for Patients with Early Alzheimer's Disease
The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration
Biogen price target raised to $305 from $245 at Piper Sandler
Piper Sandler raised the firmās price target on Biogen (BIIB) to $305 from $245 and keeps an Overweight rating on the shares. The firm remains bullish on the shares evenā¦
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
BRUSSELS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced further data characterizing the clinical profile of dapirol...
Biogen Provides Update on Private Payer Coverage for ZURZUVAE⢠(zuranolone)
TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that many group benefit health plans now reimburse ZURZUVAE⢠(zuranolone), for the treatment of moderate or severe postpartum depression (P...
Biogen price target raised to $300 from $280 at Guggenheim
Guggenheim raised the firmās price target on Biogen (BIIB) to $300 from $280 and keeps a Buy rating on the shares.
Biogen price target raised to $270 from $251 at H.C. Wainwright
H.C. Wainwright analyst Ananda Ghosh raised the firmās price target on Biogen (BIIB) to $270 from $251 and keeps a Buy rating on the shares. The firm cites the companyāsā¦
Biogen price target raised to $275 from $255 at Freedom Broker
Freedom Broker analyst Ilya Zubkov raised the firmās price target on Biogen (BIIB) to $275 from $255 and keeps a Buy rating on the shares following the Q3 report. Biogenāsā¦
Biogen price target raised to $272 from $256 at RBC Capital
RBC Capital raised the firmās price target on Biogen (BIIB) to $272 from $256 and keeps an Outperform rating on the shares after its Q3 earnings beat. Investor focus remainsā¦
Biogen price target raised to $260 from $250 at TD Cowen
TD Cowen raised the firmās price target on Biogen (BIIB) to $260 from $250 and keeps a Buy rating on the shares. The firm updated its model following solid Q3ā¦
Biogen price target raised to $225 from $212 at Wedbush
Wedbush raised the firmās price target on Biogen (BIIB) to $225 from $212 and keeps a Neutral rating on the shares. The firm notes the company reported a roughly $168Mā¦
Biogen price target raised to $300 from $270 at UBS
UBS raised the firmās price target on Biogen (BIIB) to $300 from $270 and keeps a Buy rating on the shares. The firm sees a āpositiveā setup into the Phaseā¦
Biogen upgraded to Buy from Hold at Argus
Argus upgraded Biogen (BIIB) to Buy from Hold with a $280 price target The company has benefited in recent quarters from strength in its Rare Diseases portfolio, which more thanā¦
Biogen price target raised to $238 from $231 at Morgan Stanley
Morgan Stanley raised the firmās price target on Biogen (BIIB) to $238 from $231 and keeps an Equal Weight rating on the shares.
Biogen price target raised to $272 from $248 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firmās price target on Biogen (BIIB) to $272 from $248 and keeps a Buy rating on the shares. The firm updated its model followingā¦
Biogen price target raised to $290 from $256 at Needham
Needham analyst Ami Fadia raised the firmās price target on Biogen (BIIB) to $290 from $256 and keeps a Buy rating on the shares. The company delivered a strong Q3ā¦
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab ...
Biogen price target raised to $290 from $250 at Baird
Baird raised the firmās price target on Biogen (BIIB) to $290 from $250 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results whereā¦